<DOC>
	<DOCNO>NCT00044993</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Inserting p53 gene tumor may increase effectiveness chemotherapy drug make tumor cell sensitive drug . Combining chemotherapy gene therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy gene therapy treat patient stage III stage IV breast cancer .</brief_summary>
	<brief_title>Chemotherapy Combined With Gene Therapy Treating Patients Who Have Stage III Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic efficacy docetaxel , doxorubicin , Ad5CMV-p53 gene patient locally advance breast cancer . OUTLINE : Patients receive p53 gene intralesional injection day 1 2 . Patients also receive doxorubicin IV 15 minute follow 1 hour later docetaxel IV 1 hour day 1 . Treatment repeat every 3 week 6 course . After completion chemotherapy , patient reasonable response undergo surgical resection . PROJECTED ACCRUAL : A maximum 60 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Stage IIIA , IIIB ( exclude inflammatory breast carcinoma ) , IIIC OR Localized stage IV Measurable disease No metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Adequate bone marrow function Hepatic Adequate liver function Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Adequate kidney function Cardiovascular Normal cardiac function MUGA and/or echocardiogram Other No psychological , familial , sociological , geographical condition would preclude study Not pregnant nursing Fertile patient must use effective barrier method contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior gene therapy use adenoviral vector p53 gene product Chemotherapy No prior chemotherapy breast cancer Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>